Should You Buy Arbutus Biopharma Corp (ABUS) Stock Friday Morning?

Arbutus Biopharma Corp (ABUS) is lower by Friday morning, with the stock falling -1.16% in pre-market trading to 4.26. ABUS's short-term technical score of 36 indicates that the stock has traded less bullishly over the last month than 64% of stocks on the market. In the Biotechnology industry, which ranks 139 out of 146 industries, Arbutus Biopharma Corp ranks higher than 65% of stocks. Arbutus Biopharma Corp has risen 9.67% over the past month, closing at $3.48 on November 5. During this period of time, the stock fell as low as $3.11 and as high as $6.50. ABUS has an average analyst recommendation of Strong Buy. The company has an average price target of $6.00.

ABUS has an Overall Score of 56. Find out what this means to you and get the rest of the rankings on ABUS!

See Full ABUS Report

Arbutus Biopharma Corp has a Long-Term Technical rank of 93. This means that trading over the last 200 trading days has placed the company in the upper half of stocks with 7% of the market scoring higher. In the Biotechnology industry which is number 140 by this metric, ABUS ranks better than 96% of stocks.

Important Dates for Investors in ABUS:

-Arbutus Biopharma Corp is set to release earnings on 2/2/2022. During their last earnings release the company posted EPS of $-0.91. -We do not have a set dividend date for Arbutus Biopharma Corp at this time. Click Here To Get The Full Report on Arbutus Biopharma Corp (ABUS)